
    
      The treatment is organized into blocks of 9 weeks, with pembrolizumab treatment planned for
      weeks 1, 4 and 7. On the second and third blocks, interleukin-2 is added, for 5 doses at a
      time, one dose every 8 hours, on a weekly schedule on the two weeks after the week 1 and the
      week 4 pembrolizumab doses.

      There is no dose escalation portion: The dose and schedule of IL-2 is fixed, 600,000
      IU/kg/dose, with a cap of 66 mIU/dose. Doses may be omitted for safety. The dose of
      pembrolizumab is fixed, flat dose 200 mg/dose.
    
  